William Blair Comments on CVRx’s Q1 Earnings (NASDAQ:CVRX)

CVRx, Inc. (NASDAQ:CVRX) – Research analysts at William Blair cut their Q1 2025 EPS estimates for CVRx in a note issued to investors on Tuesday, April 8th. William Blair analyst M. Andrew now anticipates that the company will earn ($0.71) per share for the quarter, down from their prior forecast of ($0.64). William Blair has a “Outperform” rating on the stock. The consensus estimate for CVRx’s current full-year earnings is ($1.91) per share. William Blair also issued estimates for CVRx’s Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.52) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($2.23) EPS, Q1 2026 earnings at ($0.71) EPS, Q2 2026 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.37) EPS and FY2026 earnings at ($2.11) EPS.

CVRx (NASDAQ:CVRX) last released its earnings results on Tuesday, February 4th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). CVRx had a negative return on equity of 93.06% and a negative net margin of 116.91%.

CVRX has been the topic of several other research reports. Lake Street Capital cut their price target on CVRx from $19.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday. Craig Hallum increased their target price on CVRx from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Friday, January 17th. Canaccord Genuity Group reduced their price target on CVRx from $23.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Piper Sandler upped their price target on shares of CVRx from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 5th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.83.

CVRx Price Performance

Shares of CVRX opened at $6.23 on Friday. CVRx has a fifty-two week low of $5.87 and a fifty-two week high of $18.55. The firm’s 50-day simple moving average is $12.20 and its two-hundred day simple moving average is $12.86. The stock has a market cap of $162.20 million, a PE ratio of -2.32 and a beta of 1.34. The company has a debt-to-equity ratio of 0.69, a quick ratio of 10.23 and a current ratio of 12.06.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC increased its holdings in CVRx by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company’s stock worth $49,000 after buying an additional 1,186 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of CVRx by 1,469.3% in the first quarter. GAMMA Investing LLC now owns 4,598 shares of the company’s stock worth $56,000 after acquiring an additional 4,305 shares during the period. Quarry LP purchased a new position in shares of CVRx during the fourth quarter valued at approximately $69,000. MetLife Investment Management LLC purchased a new position in shares of CVRx during the fourth quarter valued at approximately $111,000. Finally, Wells Fargo & Company MN lifted its position in CVRx by 86.1% during the fourth quarter. Wells Fargo & Company MN now owns 8,894 shares of the company’s stock valued at $113,000 after purchasing an additional 4,115 shares during the period. Hedge funds and other institutional investors own 75.27% of the company’s stock.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.